I-T survey for Rs 42cr land deal; will take action: Dishman

The income tax department's surveyed Dishman Pharma's premises over the weekend for taxation issues in a Rs 42 crore land deal involving Dishman SEZ and Dishman Pharma.

Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma

Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.

Contract research to boost performance in FY13: Dishman

In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.

Dishman Pharma to repay Rs 100cr debt in FY13

Pharma player Dishman Pharma is looking to cut its debt of Rs 100 crore in FY13. JR Vyas, managing director, Dishman Pharma told CNBC-TV18 that the company would be selling its SEZ land to repay debt.

Dishman Pharma expects 25% growth in FY13

Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

Better R&D income led to jump in profits: Dishman Pharma

Managing director of Dishman Pharma tells CNBC-TV18 that higher earnings from its contract revenue business is what led to the surge in third quarter profits.

Creapharm buy funded via internal accruals: Dishman Pharma

Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.

FY12 profit to be better than FY11: Dishman Pharma

Dishman's Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13.

Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

Dishman Pharma expects a 15% growth in FY12

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.

Dishman Pharma expects 15% consolidated growth, says CFO

In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.

Dishman Pharma eyes 15% topline, bottomline growth in FY12

In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.

Dishman Pharma eyes 15% growth in FY12

VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.